Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P128 | DOI: 10.1530/endoabs.56.P128

1Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Science, Poznań, Poland; 2Department of Histology and Embryology, Poznan University of Medical Science, Poznań, Poland; 3Department of General, Endocrinological and Gastroenterological Surgery, Poznan University of Medical Science, Poznań, Poland; 4Department of Nephrology, Transplantology and Internal Medicine, Poznan University of Medical Science, Poznań, Poland; 5Department of General and Transplantation Surgery, Poznan University of Medical Science, Poznań, Poland.


Purpose: Adrenal cancers are relatively rare, but they have poor prognosis. IGF2 has been confirmed as a factor of adrenal tumors development. Recent data indicate that ghrelin may be an essential factor in cancerogenesis. The aim of our study was to assess ghrelin expression in adrenal tumors, and to investigate the relationship between ghrelin, IGF2 and the clinicopathological characteristics. We also investigated the influence of ghrelin on adenocarcinoma cell line proliferation in in vitro analysis.

Materials and methods: The study group included 77 patients diagnosed with adrenal tumors, qualified for adrenalectomy. All patients underwent physical examination, laboratory testing, and computer tomography scan before the operation. Expression of ghrelin and IGF2 in adrenal tumors: 30 adenoma, 12 hyperplasia, 8 myelolipoma, 20 pheochromocytoma, 7 carcinoma and 7 unchanged adrenal glands were estimated with RT qPCR. All parameters were compared in examined groups and correlations between them were estimated. H295R cell line was stimulated by ghrelin to assess proliferation and migration.

Results: We found ghrelin overexpression in adrenal cancers, while the lowest level of ghrelin expression was observed in the control group. Ghrelin expression was 21 times higher in carcinoma (P=0.017); 2.4 times higher in adenoma (P=0.029). There were no statistical differences between myelolipoma (P=0.093) and pheochromocytoma (P=0.204) in relation to control. Ghrelin was statistically higher in carcinoma compared to adenoma (P=0.049). The positive correlation between ghrelin and IGF2 expression was observed only in myelolipoma (P=0.001). Ghrelin in concentrations of 1×10−6 M and 1×10−8 M significantly stimulated proliferation and migration in the H295R cell line.

Conclusion: Ghrelin may be involved in adrenal tumors development.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.